Opus Genetics, Inc. (IRD)
NASDAQ: IRD · Real-Time Price · USD
3.780
0.00 (0.00%)
Aug 6, 2026, 10:30 AM EDT - Market open
Opus Genetics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 88.81 | 45.09 | 30.32 | 50.5 | 42.63 | 24.53 |
Short-Term Investments | - | - | 0 | 0.02 | 0.05 | 0.22 |
Cash & Short-Term Investments | 88.81 | 45.09 | 30.32 | 50.52 | 42.68 | 24.75 |
Cash Growth | 173.87% | 48.70% | -39.97% | 18.35% | 72.44% | 50.94% |
Accounts Receivable | 1.46 | 3.17 | 5.77 | 2.33 | 4.85 | - |
Other Current Assets | 2.53 | 1.79 | 0.52 | 1.1 | 1.45 | 1.31 |
Total Current Assets | 92.7 | 50.04 | 36.61 | 53.95 | 48.99 | 26.07 |
Net Property, Plant & Equipment | 0.17 | 0.2 | 0.25 | - | 0.01 | 0.01 |
Total Assets | 92.97 | 50.24 | 36.86 | 53.95 | 48.99 | 26.08 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 1.88 | 3.29 | 3.15 | 2.15 | 1.07 | 1.58 |
Accrued Expenses | 5.72 | 4.49 | 8.15 | 1.82 | 1.68 | 1.73 |
Short-Term Debt | - | - | - | - | - | 0.54 |
Other Current Liabilities | - | - | - | 0.07 | - | - |
Total Current Liabilities | 7.61 | 7.78 | 11.3 | 4.04 | 2.75 | 3.86 |
Long-Term Debt | 34.93 | - | - | - | - | - |
Other Long-Term Liabilities | 63.42 | 27.11 | - | - | - | - |
Total Long-Term Liabilities | 98.35 | 27.11 | - | - | - | - |
Total Liabilities | 105.95 | 34.9 | 11.3 | 4.04 | 2.75 | 3.86 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.01 | 0.01 | 0 | 0 | 0 | 0 |
Additional Paid-in Capital | 249.23 | 203.93 | 145.72 | 131.37 | 117.72 | 111.59 |
Retained Earnings | -262.22 | -188.59 | -139 | -81.47 | -71.48 | -89.37 |
Total Common Shareholders' Equity | -12.99 | 15.35 | 6.72 | 49.91 | 46.24 | 22.22 |
Minority Interest | - | - | 18.84 | - | - | - |
Shareholders' Equity | -12.99 | 15.35 | 6.72 | 49.91 | 46.24 | 22.22 |
Total Liabilities & Equity | 92.97 | 50.24 | 36.86 | 53.95 | 48.99 | 26.08 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 34.93 | 0 | 0 | 0 | 0 | 0.54 |
Net Cash (Debt) | 53.88 | 45.09 | 30.32 | 50.52 | 42.68 | 24.22 |
Net Cash Growth | 66.15% | 48.70% | -39.97% | 18.35% | 76.27% | 47.66% |
Net Cash Per Share | 0.62 | 0.72 | 1.14 | 2.34 | 2.07 | 1.63 |
Book Value | -12.99 | 15.35 | 6.72 | 49.91 | 46.24 | 22.22 |
Book Value Per Share | -0.15 | 0.25 | 0.25 | 2.31 | 2.24 | 1.50 |
Tangible Book Value | -12.99 | 15.35 | 6.72 | 49.91 | 46.24 | 22.22 |
Tangible Book Value Per Share | -0.15 | 0.25 | 0.25 | 2.31 | 2.24 | 1.50 |